2P Kwan,A Arzimanoglou,A Berg,et al. Definition of Drug Resis- tant Epilepsy: Consensus Proposal by the Ad Hoc Task Force of the ILAE Commission on Therapeutic Strategies[J]. Akt Neurol, 2010,37(8) :372-381.
5Ameer Y Taha,Marc-Olivier Trepanier,Flaviu A. A minimum of 3 months of dietary fish oil supplementation is required to raise amygdaloid after discharge seizure thresholds in rats-implications for treating complex partial seizures[J]. Epilepsy and Behavior, 2013.27( 1 ) :49-58.
7Robert E Elliott, Amr Morsi, Stephen P KalhorrrVagus nerve stimu- lation in 436 consecutive patients with treatment-resistant epilep- sy:Long-term outcomes and predictors of response[J].Epilepsy and Behavior, 2010,20 ( 1 ) : 57-63.
6Labate A, Colosimo E, Gambardella A,et al. Levetiracetam in patients with generalized epilepsy andmyoclonic seizures: an open label study. Seizure,2006,15(3) :214-218.
7Kaminski RM, Matagne A, Patsalos PN, et al. Benefit of combina- tion therapy in epilepsy:a review of the preclinical evidence with levetiracetam. Epilepsia, 2009,50(3) : 387-397.
8Steinhof B J, Trink E, Wieser HG. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Ger- many and Switzerland. Seizure,2005,14(7):490-496.
9Rafal MK,Michel G,Karine L,et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant ef-ficacy of levetiracetam. Epilepsia,2009,50(7) : 1729-1740.
